Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 1998

View Archived Issues

DuPont Merck's investigational ultrasound agent shows promise in phase III

Biomira and Chiron expand Theratope cancer vaccine agreement

Company Profile: Antigenics

Scientists uncover genetic mutations responsible for hereditary form of dementia

SDZ-WAG-994 useful for cardiovascular/metabolic complications in diabetes

Ciblex formed to exploit Exhibin technology

ISIS-2302 exhibits promising activity in phase II study for Crohn's disease

Agents for CMV and other herpesvirus infections described by P&U

PTPase active-site modulators from Ontogen: a novel approach to treating diabetes

Topical antiinflammatory corticosteroid approved for marketing in Japan

Insulin sensitizers developed at JT with potent hypoglycemic effects

ADIR describes new PDE IV-inhibitory flavones

Tetrahydrobenzo[a]fluorenes for postmenopausal symptoms and related disorders

CGRP receptor antagonists developed at SKB

Yissum discloses peptidomimetic protein farnesyltransferase inhibitors

New dihydrofolate reductase inhibitors with antitumor and antiparasitic activities

Santen evaluates LTA4 hydrolase inhibitor in models of dermatitis

Suntory initiates clinical testing of three new compounds

FDA extends review period for Thyrogen

Merck & Co. and Banyu collaborate on development of ET antagonist

Memric development on hold, SKB says

HT-PS system validation triggers Cadus equity investment in Axiom

Genome Therapeutics and Astra Research Center Boston extend alliance

Dopascan studied extensively for diagnosis of Parkinson's disease

Beta3-adrenoceptor agonist CL-316243 enhances insulin activity in humans

New dosing regimen of Avax melanoma vaccine results in improved outcome

Insulin sensitizer induces ovulation in women with PCOS

Potent in vivo antifungal activity of cordycepin in combination with ADA inhibitor

Xoma issued U.S. patent for new method of humanizing monoclonal antibodies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....